This study demonstrates a new molecule that regulates AKT via the PI3K pathway, suggesting that TMCO3 can serve as a novel biomarker for HCC and potentially provide a therapeutic target for HCC treatment. Here, SLC9D1 is linked to hepatocellular carcinoma.